The Kilovoltage Intrafraction Monitoring Real-Time Prostate Cancer Image Guided Radiation Therapy Technology Journey: From Clinical Trials to Your Clinic
International Journal of Radiation Oncology*Biology*Physics · 2026
DOI: 10.1016/j.ijrobp.2026.01.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Paul J Keall und 14 weiteren Autor:innen. Beteiligte Einrichtung: Image X Institute, University of Sydney, Sydney, New South Wales, Australia. Electronic address: paul.keall@sydney.edu.au. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiotherapy, Image-Guided, Radiosurgery. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Research UK, Kræftens Bekæmpelse.
Abstract (Originalsprache)
PURPOSE: Stereotactic Body Radiation Therapy (SBRT) schedules for prostate cancer are emerging as a standard treatment approach. However, although high efficacy is achieved in clinical trials, additional efforts at accurate treatment delivery are necessary to maximize the therapeutic ratio in the community setting. Kilovoltage Intrafraction Monitoring (KIM) is a technology developed to address the unmet clinical need of accurate intrafraction motion management without a requirement for additional hardware on standard linear accelerators. This paper describes the journey from bench to bedside of KIM. METHODS AND MATERIALS: The concept of KIM emerged in 2008 in a series of simulations, progressing to phantom experiments commencing in 2010, culminating in the first clinical trial starting in 2014. A series of technical innovations integrating rotational prostate movements, quality assurance, and dynamic multileaf collimator tracking were included within the multi-institutional Trans-Tasman Radiation Oncology Group 15.01 Stereotactic Prostate Adaptive Radiation therapy using KIM clinical trial for prostate SBRT. RESULTS: Submillimeter accuracy of KIM was observed in simulations, phantom experiments, and clinical trials. The Stereotactic Prostate Adaptive Radiation therapy using KIM trial demonstrated multicenter feasibility of use, a high rate of intrafraction motion triggering a gating event, and a significant dosimetric impact of KIM deployment for target volume coverage. KIM is being made available through commercialization with an industry partner, and through a 300-patient, 10-center clinical trial. CONCLUSIONS: The collaboration between researchers, clinicians, and industry has led to KIM being developed from a concept to clinical trials, enabling the safe delivery of prostate cancer SBRT in the presence of intrafraction motion. This journey provides a template for similar bench-to-bedside translational research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Image X Institute, University of Sydney, Sydney, New South Wales, Australia. Electronic address: paul.keall@sydney.edu.au.
- Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia; Institute of Medical Physics, School of Physics, University of Sydney, Sydney, Australia.
- Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Image X Institute, University of Sydney, Sydney, New South Wales, Australia.
- Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California; University of California Jonsson Comprehensive Cancer Center, Los Angeles, California.
- GenesisCare, Alexandria, New South Wales, Australia; School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia; Centre for Medical Radiation Physics, University of Wollongong, Wollon…
Förderung
- NCI NIH HHS
- Cancer Research UK
- Kræftens Bekæmpelse
- National Institutes of Health
- Cancer Institute NSW
- US Department of Defense
- Cancer Australia
- National Health and Medical Research Council
Zitieren
APA
Keall, P. J., Booth, J., Eade, T., Hewson, E. A., Kishan, A. U., Jameson, M., Kandasamy, K., Kneebone, A., Nguyen, D. T., Poulsen, P. R., Sengupta, C., Spratt, D. E., Tree, A., Zhang, P., & Martin, J. (2026). The Kilovoltage Intrafraction Monitoring Real-Time Prostate Cancer Image Guided Radiation Therapy Technology Journey: From Clinical Trials to Your Clinic. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.01.010
Vancouver
Keall PJ, Booth J, Eade T, Hewson EA, Kishan AU, Jameson M, et al. The Kilovoltage Intrafraction Monitoring Real-Time Prostate Cancer Image Guided Radiation Therapy Technology Journey: From Clinical Trials to Your Clinic. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.01.010
BibTeX
@article{Keall2026,
author = {Keall, Paul J and Booth, Jeremy and Eade, Thomas and Hewson, Emily A and Kishan, Amar U and Jameson, Michael and Kandasamy, Kankean and Kneebone, Andrew and Nguyen, Doan Trang and Poulsen, Per Rugaard and Sengupta, Chandrima and Spratt, Daniel E and Tree, Alison and Zhang, Pengpeng and Martin, Jarad},
title = {The Kilovoltage Intrafraction Monitoring Real-Time Prostate Cancer Image Guided Radiation Therapy Technology Journey: From Clinical Trials to Your Clinic},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
doi = {10.1016/j.ijrobp.2026.01.010}
}
EUVIMED